Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effects of a Powered Lower-Limb Exoskeleton on Walking Performance in Older Adults (E-WALK)

2. juni 2026 opdateret af: Yang Zhang, Hunan Normal University

Acute Effects of a Powered Lower-Limb Exoskeleton on Walking Performance in Community-Dwelling Older Adults: A Randomized Crossover Trial

The goal of this clinical trial is to learn whether a powered wearable lower-limb exoskeleton can improve walking performance in independently ambulatory older adults aged 65 to 75 years.

The main questions it aims to answer are:

  • Does use of a powered lower-limb exoskeleton increase comfortable walking speed over 10 meters?
  • Does use of a powered lower-limb exoskeleton increase average walking speed during a 400-meter walk?

Researchers will compare walking performance in older adults during walking with the powered exoskeleton and walking without the device to determine whether the exoskeleton improves mobility. Young-adult reference participants will also complete walking assessments to provide reference values for walking performance.

Participants will:

  • Attend a screening and familiarization visit.
  • Complete walking assessments with and without the powered exoskeleton in randomized order (older adults only).
  • Perform a 10-meter walk test, a 400-meter walk test, and other physical performance assessments.
  • Complete questionnaires about balance confidence, fear of falling, and device usability.
  • Be monitored for safety events during testing.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Detaljeret beskrivelse

Age-related decline in mobility is associated with reduced independence, lower quality of life, and increased risk of disability and adverse health outcomes. Walking performance is a clinically meaningful indicator of functional status in older adults, and preservation of mobility is a major goal of healthy aging. Although exercise and rehabilitation interventions can improve mobility, their benefits typically require repeated training and sustained adherence. Technologies that provide immediate assistance during walking may offer a complementary approach to supporting mobility in older adults.

Powered wearable lower-limb exoskeletons are designed to provide external mechanical assistance during locomotion. Previous studies have shown that lower-limb exoskeletons can reduce the metabolic cost of walking and improve walking performance under laboratory conditions. However, less is known about the acute effects of commercially available exoskeleton systems on clinically relevant walking outcomes in independently ambulatory older adults.

This study will evaluate the acute effects of a commercially available powered lower-limb exoskeleton on walking performance in community-dwelling older adults. The primary outcomes are comfortable gait speed during a 10-meter walk test and average walking speed during a 400-meter walk test. Secondary outcomes include lower-extremity physical performance, physiological responses during walking, perceived exertion, balance confidence, fear of falling, device usability, participant satisfaction, and safety outcomes.

The study uses a randomized crossover design. Older adult participants will complete two experimental conditions in randomized order: walking without the exoskeleton and walking with the powered exoskeleton. Participants will attend a screening and familiarization visit followed by two trial visits separated by at least 48 hours. During the familiarization visit, participants will receive device fitting and supervised practice with the exoskeleton. At each trial visit, participants will complete standardized walking and physical performance assessments under the assigned condition.

A young-adult reference group will complete no-device walking assessments to provide reference values for walking performance. Exploratory analyses will examine whether exoskeleton-assisted walking reduces the performance gap between older adults and young adults.

The study hypothesis is that use of the powered exoskeleton will improve both short-distance and sustained walking performance in older adults and partially reduce the mobility performance gap between older and young adults.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Older adults aged 65 to 75 years who are community-dwelling, independently ambulatory, able to walk independently on level ground, able to maintain standing balance without personal assistance, and able to understand study instructions.
  • Young-adult reference participants aged 18 to 22 years who are healthy university students without known conditions affecting walking or balance.

Exclusion Criteria:

  • Self-reported neurological disease affecting gait or balance.
  • Major musculoskeletal injury or surgery affecting walking within the previous 6 months.
  • Uncontrolled cardiopulmonary disease.
  • Severe visual or vestibular impairment affecting safe walking.
  • Current lower-limb pain that limits walking.
  • Cognitive impairment that prevents informed consent or protocol adherence.
  • Any condition judged by the study team to make participation unsafe.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Older Adults
Community-dwelling older adults aged 65-75 years who complete walking assessments under both no-device and powered-exoskeleton conditions in randomized order using a crossover design. Participants attend a screening and familiarization visit followed by two trial visits.
A commercially available powered wearable lower-limb exoskeleton (VIATRIX; ULS Robotics Co., Ltd., Shanghai, China) designed to provide bilateral lower-limb assistance during walking. The device is worn around the pelvis and lower limbs and provides powered assistance through bilateral actuation. During powered-device assessments, participants use the adaptive assistive walking mode following device fitting and familiarization procedures.
Ingen indgriben: Young Adult Reference Participants
Healthy young adults aged 18-22 years who complete no-device walking assessments to provide reference values for walking performance. Participants are not randomized and do not receive the powered exoskeleton intervention.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
10-Meter Comfortable Gait Speed
Tidsramme: During each trial visit following completion of the assigned study condition (up to 5 days)
Comfortable gait speed (m/s) measured during a 10-meter walk test. Participants walk at their usual comfortable speed along a flat indoor walkway. Two trials are completed, and the mean gait speed is used for analysis.
During each trial visit following completion of the assigned study condition (up to 5 days)
400-Meter Average Walking Speed
Tidsramme: During each trial visit following completion of the assigned study condition (up to 5 days)
Average walking speed (m/s) measured during a 400-meter walk test. Participants walk 400 meters at a self-selected comfortable speed on an indoor walkway. Average walking speed is calculated as total walking distance divided by total completion time.
During each trial visit following completion of the assigned study condition (up to 5 days)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Short Physical Performance Battery Score
Tidsramme: During each trial visit following the assigned study condition, up to 5 days.
Lower-extremity physical performance assessed using the Short Physical Performance Battery. The test includes standing balance, short-distance gait speed, and repeated chair-stand performance. Component scores are summed to produce a total score ranging from 0 to 12, with higher scores indicating better physical performance.
During each trial visit following the assigned study condition, up to 5 days.
Mean Heart Rate During the 400-Meter Walk
Tidsramme: During each trial visit following the assigned study condition, up to 5 days.
Mean heart rate recorded continuously during the 400-meter walk test using a wrist-worn optical heart-rate monitor.
During each trial visit following the assigned study condition, up to 5 days.
Borg Rating of Perceived Exertion
Tidsramme: Immediately after the 400-meter walk test during each trial visit, up to 5 days.
Perceived exertion assessed immediately after the 400-meter walk test using the Borg Rating of Perceived Exertion scale.
Immediately after the 400-meter walk test during each trial visit, up to 5 days.
Fear of Falling 10-Rating Scale Score
Tidsramme: After physical performance testing during each trial visit, up to 5 days.
Immediate fear of falling assessed after each trial condition using the Fear of Falling 10-Rating Scale, with instructions referring to the walking and physical performance tests completed during that visit.
After physical performance testing during each trial visit, up to 5 days.
Activities-specific Balance Confidence Scale Score
Tidsramme: After physical performance testing during each trial visit, up to 5 days.
Balance confidence assessed using the Activities-specific Balance Confidence Scale after each trial condition.
After physical performance testing during each trial visit, up to 5 days.
System Usability Scale Score
Tidsramme: After completion of the powered-device trial visit, up to 5 days.
Perceived usability of the powered lower-limb exoskeleton assessed after the powered-device condition using the System Usability Scale.
After completion of the powered-device trial visit, up to 5 days.
Quebec User Evaluation of Satisfaction With Assistive Technology 2.0 Device Subscale Score
Tidsramme: After completion of the powered-device trial visit, up to 5 days.
Participant satisfaction with the powered lower-limb exoskeleton assessed after the powered-device condition using the device subscale of the Quebec User Evaluation of Satisfaction with Assistive Technology 2.0.
After completion of the powered-device trial visit, up to 5 days.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Falls
Tidsramme: From enrollment through completion of the final study visit, up to 5 days.
Number of falls occurring during study procedures. A fall is defined as an event in which the participant comes to rest inadvertently on the ground, floor, or another lower level.
From enrollment through completion of the final study visit, up to 5 days.
Number of Near-Loss-of-Balance Events
Tidsramme: From enrollment through completion of the final study visit, up to 5 days.
Number of near-loss-of-balance events occurring during study procedures. A near-loss-of-balance event is defined as an observable unintended balance disturbance requiring a corrective response to prevent a fall.
From enrollment through completion of the final study visit, up to 5 days.
Number of Device-Related Adverse Events
Tidsramme: From enrollment through completion of the final study visit, up to 5 days.
Number of adverse events judged to be caused by, probably caused by, or associated with use of the powered lower-limb exoskeleton.
From enrollment through completion of the final study visit, up to 5 days.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Yang Zhang, PhD

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. juli 2026

Primær færdiggørelse (Anslået)

1. oktober 2026

Studieafslutning (Anslået)

1. oktober 2026

Datoer for studieregistrering

Først indsendt

2. juni 2026

Først indsendt, der opfyldte QC-kriterier

2. juni 2026

Først opslået (Faktiske)

8. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner